FrancophonIA/ELRC3.0 huggingface dataset:
English: c.1018T>C or c.1018T>A c.T1018C or c.T1018A
Swedish: c.1018T>C eller c.1018T>A c.T1018C eller c.T1018A
English: If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
Swedish: Om du är gravid, tror att du kan vara gravid eller planerar att skaffa barn, rådfråga läkare, apotekspersonal eller sjuksköterska innan du använder detta läkemedel.
English: In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p< 0.05); the mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27).
Swedish: I den ERT-naiva prövningen resulterade Galafold i en statistiskt signifikant minskning av LVMi (p< 0,05); den genomsnittliga förändringen från baseline i LVMi vid månad 18 till 24 var -7,7 (95-procentigt KI: -15,4, -0,01; n=27).
English: (dyspnoea)
Swedish: (dyspepsi)
English: If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Swedish: Om du har ytterligare frågor om användningen av detta läkemedel, kontakta läkare, apotekspersonal eller sjuksköterska.
English: Disease Substrate
Swedish: Sjukdomssubstrat
English: c.G611A or G612A
Swedish: c.G611A eller G612A
English: Migalastat did not affect fertility in female rats.
Swedish: Migalastat påverkade inte honråttors fertilitet.
English: The pharmacokinetic characteristics of migalastat were not significantly different between females and males in either healthy volunteers or in patients with Fabry disease.
Swedish: Migalastats farmakokinetiska egenskaper skiljde sig inte på något signifikant sätt mellan kvinnor och män.
English: c.369+3_639+954del3129insT UNKNOWN (del Exon3 and 4?)
Swedish: c.369+3_639+954del3129insT OKÄND (del Exon3 och g.6009_9741del
English: g.6736_11545del c.370-533_c.1290+277del
Swedish: OKÄND (del Exon3 och g.6736_11545del c.370-533_c.1290+277del
English: Your doctor will monitor your condition and whether your medicine is working every 6 months while you are taking Galafold.
Swedish: Medan du tar Galafold kommer din läkare var 6:e månad att övervaka ditt tillstånd och kontrollera om läkemedlet verkar.
English: c.140G>A or 141G>A
Swedish: c.140G>A eller 141G>A
English: To access the package leaflet, scan the code below.
Swedish: Skanna in nedanstående kod för att komma åt bipacksedeln.
English: c.T1147C or c.C1149G or c.C1149A
Swedish: c.T1147C eller c.C1149G eller c.C1149A
English: Hepatic impairment No dosage adjustment of Galafold is required in patients with hepatic impairment (see section 5.2).
Swedish: Nedsatt leverfunktion Ingen dosjustering av Galafold är nödvändig hos patienter med nedsatt leverfunktion (se avsnitt 5.2).
English: c.611G>A or 612G>A
Swedish: c.611G>A eller 612G>A
English: c.A504C or c.A504T
Swedish: c.A504C eller c.A504T
English: 92.9 g/m for the ERT arm and the mean change from baseline in LVMi at Month 18 was -6.6 (95% CI: -11.0, -2.1; n=31) for Galafold and -2.0 (95% CI: -11.0, 7.0; n=13) for ERT.
Swedish: 92,9 g/m för ERT-gruppen, och den genomsnittliga förändringen av LVMi från baslinjen månad 18 var -6,6 (95-procentigt KI: -11,0, -2,1; n=31) för Galafold och -2,0 (95-procentigt KI: -11,0, 7,0; n=13) för ERT.
English: Dyspnoea Epistaxis
Swedish: Dyspné Epistaxis
English: c.712A>C or c.714T>A or c.714T>G
Swedish: c.712A>C eller c.714T>A eller c.714T>G
English: g.2594_10904dup c.195-2500_999+197dup
Swedish: g.2594_10904dup c.195-2500_999+197dup g.2934_6378del
English: On your first day of taking this medicine from a new blister sleeve, record the date on the blister sleeve.
Swedish: Skriv ner datumet på blisterfodralet den första dagen du tar detta läkemedel från ett nytt blisterfodral.
English: c.442A>C or c.444T>A or c.444T>G
Swedish: c.442A>C eller c.444T>A eller c.444T>G
English: The mean change from baseline in LVMi at Month 18 to 24 in patients with left ventricular hypertrophy at baseline (females with baseline LVMi > 95 g/m or males with baseline LVMi > 115 g/m 2) was -18.6 (95% CI: -38.2, 1.0; n=8).
Swedish: Den genomsnittliga förändringen från baseline i LVMi vid månad 18 till 24 hos patienter med vänsterkammarhypertrofi (kvinnor med baseline LVMi > 95 g/m och män med baseline LVMi > 115 g/m2) var -18,6 (95-procentigt KI: -38,2,
English: c.A924T or c.A924C
Swedish: c.A924T eller c.A924C
English: (proteinuria)
Swedish: (proteinuri)
English: c.G140A or G141A
Swedish: c.G140A eller G141A
English: c.504A>C or c.504A>T
Swedish: c.504A>C eller c.504A>T
English: g.10237_11932del/11933_12083i nv/12084_12097del
Swedish: g.10237_11932del/11933_12083i nv/12084_12097del g.>5.5kbdel to 3UTR
English: c.924A>T or c.924A>C
Swedish: c.924A>T eller c.924A>C
English: c.G412A or c.G412C
Swedish: c.G412A eller c.G412C
English: Galafold has not been studied in patients with Fabry disease who have a GFR less than 30 mL/min/1.73 m2.
Swedish: Galafold har inte studerats hos patienter med Fabrys sjukdom som har en GFR under 30 ml/min/1,73 m2.
English: c.1147T>C or c.1149C>G or c.1149C>A
Swedish: c.1147T>C eller c.1149C>G eller c.1149C>A
English: c.148T>C or c.150C>G or c.150C>A
Swedish: c.148T>C eller c.150C>G eller c.150C>A
English: c.561G>T or c.561G>A or c.561G>C
Swedish: c.561G>T eller c.561G>A eller c.561G>C
English: c.A124C or c.A124T
Swedish: c.A124C eller c.A124T
English: Paraesthesia Dizziness Hypoaesthesia
Swedish: Parestesi Yrsel Hypestesi
English: c.70T>C or c.70T>A
Swedish: c.70T>C eller c.70T>A
English: c.280T>A or c.281G>C
Swedish: c.280T>A eller c.281G>C
English: c.1045T>C or c.1045T>A c.T1045C or c.T1045A
Swedish: c.1045T>C eller c.1045T>A c.T1045C eller c.T1045A
English: c.T187A or c.G188C
Swedish: c.T187A eller c.G188C
English: - If you have any further questions, ask your doctor, pharmacist, or nurse.
Swedish: - Om du har ytterligare frågor, vänd dig till läkare, apotekspersonal eller sjuksköterska.
English: c.1095T>A or c.1095T>G c.T1095A or c.T1095G
Swedish: c.1095T>A eller c.1095T>G c.T1095A eller c.T1095G
English: How to store Galafold
Swedish: Hur Galafold ska förvaras
English: c.216G>A or c.216G>T or c.216G>C
Swedish: c.216G>A eller c.216G>T eller c.216G>C
English: c.G982A or c.G982C
Swedish: c.G982A eller c.G982C
English: c.817T>C or c.819T>A or c.819T>G
Swedish: c.817T>C eller c.819T>A eller c.819T>G
English: c.412G>A or c.412G>C
Swedish: c.412G>A eller c.412G>C
English: Instructions to open
Swedish: Öppningsanvisningar
English: c.337T>C or c.339T>A or c.339T>G
Swedish: c.337T>C eller c.339T>A eller c.339T>G
English: c.G285T or c.G285C
Swedish: c.G285T eller c.G285C
English: c.71G>A or c.72G>A
Swedish: c.71G>A eller c.72G>A
English: • Reduced sense of touch or sensation
Swedish: • Minskad känslighet för beröring (hypestesi)
English: c.T148C or c.C150G or c.C150A F50L
Swedish: c.T148C eller c.C150G eller c.C150A
English: In the ERT-experienced trial, following 18 months of treatment with Galafold there was a statistically significant decrease in LVMi (p< 0.05).
Swedish: Index av vänsterkammarmassa (Left Ventricular Mass Index, LVMi) I den ERT-erfarna prövningen sågs en statistiskt signifikant minskning av LVMi (p< 0,05) efter 18 månaders behandling med Galafold.
English: c.T70C or c.T70A
Swedish: c.T70C eller c.T70A
English: c.982G>A or c.982G>C
Swedish: c.982G>A eller c.982G>C
English: c.228G>C or c.228G>A or c.228G>T
Swedish: c.228G>C eller c.228G>A eller c.228G>T
English: c.G540C or c.G540T
Swedish: c.G540C eller c.G540T
English: After follow up in the OLE, the mean change from baseline in LVMi at Month 36 was -8.3 (95% CI: -17.1, 0.4; n=25) and at Month 48 was -9.1 (95% CI: -20.3, 2.0; n=18).
Swedish: Efter uppföljning i den öppna förlängningsstudien var den genomsnittliga förändringen från baseline i LVMi vid månad 36 -8,3 (95-procentigt KI: -17,1, 0,4, n = 25) och vid månad 48 -9,1 (95-procentigt KI: -20,3, 2,0, n = 18).
English: c.G471C or c.G471T
Swedish: c.G471C eller c.G471T
English: c.T166A or c.G167C
Swedish: c.T166A eller c.G167C
English: c.G261C or c.G261T
Swedish: c.G261C eller c.G261T
English: c.G71A or c.G72A
Swedish: c.G71A eller c.G72A
English: Do not use this medicine after the expiry date, which is stated on the carton and blister after EXP.
Swedish: Används före utgångsdatum som anges på kartongen och blisterförpackningen efter EXP. Utgångsdatumet är den sista dagen i angiven månad.
English: c.187T>A or c.188G>C
Swedish: c.187T>A eller c.188G>C
English: c.261G>C or c.261G>T
Swedish: c.261G>C eller c.261G>T
English: c.612G>T or c.612G>C
Swedish: c.612G>T eller c.612G>C
English: c.124A>C or c.124A>T
Swedish: c.124A>C eller c.124A>T
English: Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GFR less than 30 mL/min/1.73m
Swedish: Galafold rekommenderas inte till patienter med allvarlig njurinsufficiens, definierat som GFR under 30 ml/min/1,73 m
English: c.G612T or c.G612C
Swedish: c.G612T eller c.G612C
English: c.285G>T or c.285G>C
Swedish: c.285G>T eller c.285G>C
English: If more than 12 hours has passed you should resume taking Galafold at the next planned dosing day and time according to your every other day dosing schedule.. Do not take two capsules to make up for your missed dose.
Swedish: Om det har gått längre tid än 12 timmar, ska du fortsätta att ta Galafold den dag och tidpunkt som anges för nästa planerade dos enligt doseringsschemat.
English: c.471G>C or c.471G>T
Swedish: c.471G>C eller c.471G>T
English: c.G132T or c.G132C
Swedish: c.G132T eller c.G132C
English: c.T514A or c.G515C
Swedish: c.T514A eller c.G515C
English: c.153G>A or c.153G>T or c.153G>C
Swedish: c.153G>A eller c.153G>T eller c.153G>C
English: c.G243T or c.G243C
Swedish: c.G243T eller c.G243C
English: c.T280A or c.G281C
Swedish: c.T280A eller c.G281C
English: c.G609C or c.G609T
Swedish: c.G609C eller c.G609T
English: UNKNOWN (del Exon3?)
Swedish: OKÄND (del Exon3?)
English: c.166T>A or c.167G>C
Swedish: c.166T>A eller c.167G>C
English: c.G144T or c.G144C
Swedish: c.G144T eller c.G144C
English: c.T784A or c.T784C
Swedish: c.T784A eller c.T784C
English: c.243G>T or c.243G>C
Swedish: c.243G>T eller c.243G>C
English: c.A840T or c.A840C
Swedish: c.A840T eller c.A840C
English: c.132G>T or c.132G>C
Swedish: c.132G>T eller c.132G>C
English: c.G567C or c.G567T
Swedish: c.G567C eller c.G567T
English: c.609G>C or c.609G>T
Swedish: c.609G>C eller c.609G>T
English: c.144G>T or c.144G>C
Swedish: c.144G>T eller c.144G>C
English: c.540G>C or c.540G>T
Swedish: c.540G>C eller c.540G>T
English: c.T154A or c.G155C
Swedish: c.T154A eller c.G155C
English: UNKNOWN (del Exon1_2?)
Swedish: OKÄND (del Exon1_2?)
English: c.A588T or c.A588C
Swedish: c.A588T eller c.A588C
English: c.G831T or c.G831C
Swedish: c.G831T eller c.G831C
English: c.G141C or c.G141T
Swedish: c.G141C eller c.G141T
English: c.567G>C or c.567G>T
Swedish: c.567G>C eller c.567G>T
English: c.108G>C or c.108G>T
Swedish: c.108G>C eller c.108G>T
English: c.141G>C or c.141G>T
Swedish: c.141G>C eller c.141G>T
English: UNKNOWN (del Exon5_7?)
Swedish: OKÄND (del Exon5_7?)
English: c.831G>T or c.831G>C
Swedish: c.831G>T eller c.831G>C
English: c.784T>A or c.784T>C
Swedish: c.784T>A eller c.784T>C
English: Protein Sequence change c.1202C>G or c.1202C>A c.C1202G or c.C1202A
Swedish: W399S c.1202C>G eller c.1202C>A c.C1202G eller c.C1202A S401X c.1215T>A
English: c.T667A or c.G668C
Swedish: c.T667A eller c.G668C
English: c.G439A or c.G439C
Swedish: c.G439A eller c.G439C
English: c.G216A or c.G216T or c.G216C M72I
Swedish: c.G216A eller c.G216T eller c.G216C
English: c.G108C or c.G108T
Swedish: c.G108C eller c.G108T
English: c.T817C or c.T819A or c.T819G F273L
Swedish: c.T817C eller c.T819A eller c.T819G
English: Galafold is not recommended for use in patients with Fabry disease who have estimated GFR less than 30 mL/min/1.73 m
Swedish: Galafold rekommenderas inte till patienter med Fabrys sjukdom med en uppskattad GFR under 30 ml/min/1,73 m
English: c.G394A or c.G394C
Swedish: c.G394A eller c.G394C
English: c.439G>A or c.439G>C
Swedish: c.439G>A eller c.439G>C
English: c.514T>A or c.515G>C
Swedish: c.514T>A eller c.515G>C
English: c.870G>A or c.870G>C or c.870G>T
Swedish: c.870G>A eller c.870G>C eller c.870G>T
English: Do not take Galafold if you:
Swedish: Ta inte Galafold
English: c.G861C or c.G861T
Swedish: c.G861C eller c.G861T
English: c.888G>A or c.888G>T or c.888G>C
Swedish: c.888G>A eller c.888G>T eller c.888G>C
English: c.T337C or c.T339A or c.T339G F113L
Swedish: c.T337C eller c.T339A eller c.T339G
English: BLISTER FOIL
Swedish: BLISTERFODRAL
English: c.394G>A or c.394G>C
Swedish: c.394G>A eller c.394G>C
English: c.154T>A or c.155G>C
Swedish: c.154T>A eller c.155G>C
English: The mean annualised rate of change from baseline in eGFRCKD-EPI in patients treated for 30 months with Galafold was -1.72 mL/min/1.73 m
Swedish: The genomsnittliga årliga förändring i eGFRCKD-EPI hos patienter behandlade med Galafold i 30 månader var -1,72 ml/min/1,73 m (95-procentigt KI: -2,653, -0,782; n=31).
English: c.G486C or c.G486T
Swedish: c.G486C eller c.G486T
English: c.1196G>A or c.1197G>A c.G1196A or c.G1197A
Swedish: E398A c.1196G>A eller c.1197G>A c.G1196A eller c.G1197A W399X c.1196G>C
English: c.G837C or c.G837T
Swedish: c.G837C eller c.G837T
English: Table 2: Galafold (migalastat) amenability table
Swedish: Tabell 2: Tabell över behandlingsbarhet med Galafold (migalastat)
English: c.708G>C or c.708G>T
Swedish: c.708G>C eller c.708G>T
English: If you are planning to have a baby, ask your doctor, pharmacist, or nurse for advice.
Swedish: Om du planerar att skaffa barn, rådfråga läkare, apotekspersonal eller sjuksköterska.
English: c.840A>T or c.840A>C
Swedish: c.840A>T eller c.840A>C
English: c.G936T or c.G936C
Swedish: c.G936T eller c.G936C
English: c.588A>T or c.588A>C
Swedish: c.588A>T eller c.588A>C
English: c.A868C or c.A868T
Swedish: c.A868C eller c.A868T
English: c.G963C or c.G963T
Swedish: c.G963C eller c.G963T
English: c.861G>C or c.861G>T
Swedish: c.861G>C eller c.861G>T
English: c.G126A or c.G126C or c.G126T M42I
Swedish: c.G126A eller c.G126C eller c.G126T
English: c.936G>T or c.936G>C
Swedish: c.936G>T eller c.936G>C
English: c.837G>C or c.837G>T
Swedish: c.837G>C eller c.837G>T
English: c.72G>C or c.72G>T
Swedish: c.72G>C eller c.72G>T
English: c.A712C or c.T714A or c.T714G S238R
Swedish: c.A712C eller c.T714A eller c.T714G
English: UNKNOWN (del Exon3_7?)
Swedish: OKÄND (del Exon3_7?)
English: c.667T>A or c.668G>C
Swedish: c.667T>A eller c.668G>C
English: c.1019G>A or c.1020G>A c.G1019A or c.G1020A
Swedish: W340R c.1019G>A eller c.1020G>A c.G1019A eller c.G1020A W340X c.1019G>C
English: c.978G>C or c.978G>T
Swedish: c.978G>C eller c.978G>T
English: c.288G>A or c.288G>T or c.288G>C
Swedish: c.288G>A eller c.288G>T eller c.288G>C
English: c.963G>C or c.963G>T
Swedish: c.963G>C eller c.963G>T
English: Galafold 123 mg hard capsules migalastat
Swedish: Galafold 123 mg hårda kapslar migalastat
English: c.486G>C or c.486G>T
Swedish: c.486G>C eller c.486G>T
English: c.G228C or c.G228A or c.G228T M76I
Swedish: c.G228C eller c.G228A eller c.G228T
English: c.720G>C or c.720G>T
Swedish: c.720G>C eller c.720G>T
English: c.678G>T or c.678G>C
Swedish: c.678G>T eller c.678G>C
English: c.G978C or c.G978T
Swedish: c.G978C eller c.G978T
English: c.C525G or c.C525A
Swedish: c.525C>G eller c.525C>A c.C525G eller c.C525A
English: c.729G>C or c.729G>T
Swedish: c.729G>C eller c.729G>T
English: c.G720C or c.G720T
Swedish: c.G720C eller c.G720T
English: c.G72C or c.G72T
Swedish: c.G72C eller c.G72T
English: UNKNOWN (del Exon2_3?)
Swedish: OKÄND (del Exon2_3?)
English: Galafold 123 mg hard capsules
Swedish: Galafold 123 mg hårda kapslar
English: c.G729C or c.G729T
Swedish: c.G729C eller c.G729T
English: c.G708C or c.G708T
Swedish: c.G708C eller c.G708T
English: c.868A>C or c.868A>T
Swedish: c.868A>C eller c.868A>T
English: c.C159G or c.C159A
Swedish: c.159C>G eller c.159C>A c.C159G eller c.C159A
English: The change from baseline to Month 18 in LVMi (g/m 2) in patients with left ventricular hypertrophy (females with baseline LVMi > 95 g/m and males with baseline LVMi > 115 g/m2) was -8.4 (95% CI: -15.7, 2.6; n=13) for migalastat and 4.5 (95% CI: -10.7, 18.4; n=5) for ERT. After 30 months treatment with Galafold, the mean change from baseline in LVMi was -3.8 (95% CI: -8.9, 1.3; n=28) and the mean change from baseline in LVMi in patients with left ventricular hypertrophy at baseline was -10.0 (95% CI: -16.6, -3.3; n=10).
Swedish: Efter 30 månaders behandling med Galafold var den genomsnittliga förändringen av LVMi från baslinje var -3,8 (95-procentigt KI: -8,9, 1,3; n=28) och den genomsnittliga förändringen från baslinjen i LVMI hos patienter med vänsterkammarhypertrofi vid baseline -10,0 (95-procentigt KI: -16,6, -3,3; n=10).
English: c.C279G or c.C279A
Swedish: c.279C>G eller c.279C>A c.C279G eller c.C279A
English: c.G678T or c.G678C
Swedish: c.G678T eller c.G678C
English: c.G561T or c.G561A or c.G561C M187I
Swedish: c.G561T eller c.G561A eller c.G561C
English: c.A886T or c.A886C
Swedish: c.A886T eller c.A886C
English: Protein Sequence change c.290delC
Swedish: Proteinsekvensförändring c.1025delG
English: c.A442C or c.T444A or c.T444G S148R
Swedish: c.A442C eller c.T444A eller c.T444G
English: c.G870A or c.G870C or c.G870T M290I
Swedish: c.G870A eller c.G870C eller c.G870T
English: c.G153A or c.G153T or c.G153C M51I
Swedish: c.G153A eller c.G153T eller c.G153C
English: c.G786C or c.G786T
Swedish: c.G786C eller c.G786T
English: c.886A>T or c.886A>C
Swedish: c.886A>T eller c.886A>C
English: c.G888A or c.G888T or c.G888C M296I
Swedish: c.G888A eller c.G888T eller c.G888C
English: BLISTER SLEEVE
Swedish: Muskelkramper Myalgi
English: c.786G>C or c.786G>T
Swedish: c.786G>C eller c.786G>T
English: Protein sequence change c.126G>A or c.126G>C or c.126G>T
Swedish: c.126G>A eller c.126G>C eller c.126G>T
English: Protein Sequence change p.T412Sfs*37
Swedish: p.T412Sfs*37
English: c.207C>A or c.207C>G
Swedish: c.207C>A eller c.207C>G c.C207A eller c.C207G
English: After follow up in the OLE, the mean change from baseline in LVMi in patients with left ventricular hypertrophy at baseline at Month 36 was -30.0 (95%) CI: -57.9, -2.2; n=4) and at Month 48
Swedish: Efter uppföljning i den öppna förlängningsstudien var den genomsnittliga förändringen från baseline i LVMi hos patienter med vänsterkammarhypertrofi vid månad 36 lika med -30,0 (95procentigt KI: -57,9, -2,2, n = 4) och vid månad 48 -33,1 (95-procentigt KI: -60,9, -5,4, n = 4).
English: p.87_92del c.267_268dupCT
Swedish: Proteinsekvensförändring c.267_268dupCT
English: c.G288A or c.G288T or c.G288C M96I
Swedish: c.G288A eller c.G288T eller c.G288C
English: c.T139C or c.T139A
Swedish: c.139T>C eller c.139T>A c.T139C eller c.T139A
English: c.552T>A or c.552T>G
Swedish: c.552T>A eller c.552T>G c.T552A eller c.T552G
English: • Tingling in extremities
Swedish: • Krypningar i extremiteter (parestesi)
English: c.1034C>G or c.1034C>A c.C1034G or c.C1034A
Swedish: L344P c.1034C>G eller c.1034C>A c.C1034G eller c.C1034A S345X c.1042G>C
English: c.C305G or c.C305A
Swedish: c.305C>G eller c.305C>A c.C305G eller c.C305A
English: Protein Sequence change c.744delT
Swedish: Proteinsekvensförändring p.404delR
English: c.C747G or c.C747A
Swedish: c.747C>G eller c.747C>A c.C747G eller c.C747A
English: c.T258G or c.T258A
Swedish: c.258T>G eller c.258T>A c.T258G eller c.T258A
English: c.G284A or c.G285A
Swedish: c.284G>A eller c.285G>A c.G284A eller c.G285A
English: c.1046G>A or c.1047G>A c.G1046A or c.G1047A
Swedish: W349R c.1046G>A eller c.1047G>A c.G1046A eller c.G1047A W349X c.1048G>C
English: c.816C>A or c.816C>G
Swedish: c.816C>A eller c.816C>G c.C816A eller c.C816G
English: c.519C>A or c.519C>G
Swedish: c.519C>A eller c.519C>G c.C519A eller c.C519G
English: c.1081G>A or c.1081G>C
Swedish: c.1081G>A eller c.1081G>C c.G1081A eller c.G1081C
English: c.C897G or c.C897A
Swedish: c.897C>G eller c.897C>A c.C897G eller c.C897A
English: c.T241C or c.T241A
Swedish: c.241T>C eller c.241T>A c.T241C eller c.T241A
English: c.830G>A or c.831G>A
Swedish: c.830G>A eller c.831G>A c.G830A eller c.G831A
English: (paraesthesia)
Swedish: (pruritus)
English: c.785G>A or c.786G>A
Swedish: c.785G>A eller c.786G>A c.G785A eller c.G786A
English: c.T706C or c.T706A
Swedish: c.706T>C eller c.706T>A c.T706C eller c.T706A
English: c.G485A or c.G486A
Swedish: c.485G>A eller c.486G>A c.G485A eller c.G486A
English: c.T859C or c.T859A
Swedish: c.859T>C eller c.859T>A c.T859C eller c.T859A
English: c.T610C or c.T610A
Swedish: c.610T>C eller c.610T>A c.T610C eller c.T610A
English: g.6547_9783del
Swedish: OKÄND (del Exon3 och g.6547_9783del
English: c.C453G or c.C453A
Swedish: c.453C>G eller c.453C>A c.C453G eller c.C453A
English: c.1065C>A or c.1065C>G c.C1065A or c.C1065G
Swedish: c.456C>A eller c.456C>G c.C456A eller c.C456G
English: c.T894G or c.T894A
Swedish: c.894T>G eller c.894T>A c.T894G eller c.T894A
English: c.T102G or c.T102A
Swedish: c.102T>G eller c.102T>A c.T102G eller c.T102A
English: c.T676C or c.T676A
Swedish: c.676T>C eller c.676T>A c.T676C eller c.T676A
English: c.T402G or c.T402A
Swedish: c.402T>G eller c.402T>A c.T402G eller c.T402A
English: c.T960G or c.T960A
Swedish: c.960T>G eller c.960T>A c.T960G eller c.T960A
English: c.C233G or c.C233A
Swedish: c.233C>G eller c.233C>A c.C233G eller c.C233A
English: c.G131A or c.G132A
Swedish: c.131G>A eller c.132G>A c.G131A eller c.G132A
English: c.T484C or c.T484A
Swedish: c.484T>C eller c.484T>A c.T484C eller c.T484A
English: c.465T>A or c.465T>G
Swedish: c.465T>A eller c.465T>G c.T465A eller c.T465G
English: c.1074G>T or c.1074G>C
Swedish: c.1074G>T eller c.1074G>C c.G1074T eller c.G1074C
English: c.860G>A or c.861G>A
Swedish: c.860G>A eller c.861G>A c.G860A eller c.G861A
English: c.966C>A or c.966C>G
Swedish: c.966C>A eller c.966C>G c.C966A eller c.C966G
English: c.408T>A or c.408T>G
Swedish: c.408T>A eller c.408T>G c.T408A eller c.T408G
English: c.648T>A or c.648T>G
Swedish: c.648T>A eller c.648T>G c.T648A eller c.T648G
English: c.3G>A or c.3G>T or c.3G>C c.G3A or c.G3T or c.G3C
Swedish: c.3G>A eller c.3G>T eller c.3G>C
English: c.T702G or c.T702A
Swedish: c.702T>G eller c.702T>A c.T702G eller c.T702A
English: c.242G>A or c.243G>A
Swedish: c.242G>A eller c.243G>A c.G242A eller c.G243A
English: c.778G>C or c.778G>A
Swedish: c.778G>C eller c.778G>A c.G778C eller c.G778A
English: c.T834G or c.T834A
Swedish: c.834T>G eller c.834T>A c.T834G eller c.T834A
English: c.707G>A or c.708G>A
Swedish: c.707G>A eller c.708G>A c.G707A eller c.G708A
English: c.T881G or c.T881A
Swedish: c.881T>G eller c.881T>A c.T881G eller c.T881A
English: c.687T>A or c.687T>G
Swedish: c.687T>A eller c.687T>G c.T687A eller c.T687G
English: • Constipation
Swedish: • Trötthet
English: c.789T>A or c.789T>G
Swedish: c.789T>A eller c.789T>G c.T789A eller c.T789G
English: c.T369G or c.T369A
Swedish: c.369T>G eller c.369T>A c.T369G eller c.T369A
English: c.798T>A or c.798T>G
Swedish: c.798T>A eller c.798T>G c.T798A eller c.T798G
English: c.677G>A or c.678G>A
Swedish: c.677G>A eller c.678G>A c.G677A eller c.G678A
English: c.C666A or c.C666G
Swedish: c.666C>A eller c.666C>G c.C666A eller c.C666G
English: c.G734A or c.G735A
Swedish: c.734G>A eller c.735G>A c.G734A eller c.G735A
English: c.103G>C or c.103G>A
Swedish: c.103G>C eller c.103G>A c.G103C eller c.G103A
English: c.A1023C or c.A1023T
Swedish: Proteinsekvensförändring c.1023A >C eller c.1023A>T c.A1023C eller c.A1023T
English: c.772G>C or c.772G>A
Swedish: c.772G>C eller c.772G>A c.G772C eller c.G772A
English: Palpitations
Swedish: • Palpitationer
English: The proportion of patients who had at least a 75% reduction in symptoms after 16 weeks of treatment was 68% with Halimatoz and 63% with Humira.
Swedish: Andelen patienter som hade en minst 75-procentig minskning av symtomen efter 16 veckors behandling var 68 procent med Halimatoz och 63 procent med Humira.
English: Further information on Halimatoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Swedish: Mer information om Halimatoz finns på EMA:s webbplats ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Halimatoz?
Swedish: Vad görs för att garantera säker och effektiv användning av Halimatoz?